MENU
OTLK
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Outlook Therapeutics (OTLK) Ownership - Who owns Outlook Therapeutics?
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
485 Route 1 South Building F
Phone
+1 609 619-3990
Employees
24
Web
https://www.outlooktherapeutics.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
38.74M
P/E Ratio
N/A
Total Cash
5.7M
Projected Growth
N/A
Total Debt
31.03M
Revenue
N/A
Risk (Beta)
-0.29
Dividend Yield
N/A
Total Cash/Share
0.18
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
OTLK
Capitalization
38.7M
P/E Ratio
N/A
Risk (Beta)
-0.29
Dividend Yield
N/A
Total Cash
5.7M
Total Cash/Share
0.18
Total Debt
31M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-50.29M
P/B Ratio
N/A
Cash Flow
N/A
Earnings
-2.48
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
249K
Current Ratio
0.32
Current Revenue Per Employee
418109.78
Dividends Per Share - Security
N/A
EBITDA
-83.38M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-241.97
Shares Held By Institutions
13.8M
Shares Outstanding - Current
32M
Total Liabilities
67.3M
Total Volume MTD
N/A
Value
-1
Gain YTD
-35.979
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a manufacturer of biosimilar versions of biopharmaceuticals
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
485 Route 1 South Building F
Phone
+1 609 619-3990
Employees
24
Web
https://www.outlooktherapeutics.com